TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1867617
Drug: 0.25% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% plain bupivacaine (local injection)
Study: 1867617
Drug: 0.25% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% plain bupivacaine (topical application)
Study: 1867617
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl (control for local injection)
Study: 1867617
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl (control for topical application)
Study: 6409958
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc load
Study: 19758763
Drug: Cognitive intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive intervention (CI) prior to injection with CRH
Study: 14504028
Drug: BUP 8
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BUP 8 mg s.l. tablet
Study: 14504028
Drug: METH 60
Normalized name: CALCIUM CARB 1GM/SIMETH 60MG CHEW TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: METH 60 mg/day
Study: 380909
Drug: Amineptine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amineptine (200 mg per day)
Study: 3027832
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of itraconazole daily
Study: 3027832
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of itraconazole daily
Study: 3027832
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg or 100 mg of itraconazole daily
Study: 29484877
Drug: Neurologic music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurologic music therapy for 16 weeks in addition to usual physiotherapy
Study: 29484877
Drug: Usual therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual therapeutic input without neurologic music therapy
Study: 24132773
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg soft-gel capsule of acetylsalicylic acid (ASA)
Study: 24132773
Drug: marketed powder
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: marketed powder for oral solution
Study: 21626815
Drug: Akatinol memantine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Akatinol memantine (5-10 mg/day, increased to 20 mg/day over 90 days)
Study: 17592907
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole (2-15 mg/day with fluoxetine or paroxetine; 2-20 mg/day with all others)
Study: 9772598
Drug: Morphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (2 mg)
Study: 19459553
Drug: Bupivacaine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (100 mg)
Study: 12802484
Drug: Saline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (20 ml)
Study: 11836043
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2/0.5 mg NETA (low-dose HRT)
Study: 11836043
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg E2/1 mg NETA (high-dose HRT)
Study: 2023370
Drug: Beta-blockers in
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers in aqueous solution
Study: 31804186
Drug: Web-based self-titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based self-titration program
Study: 26446331
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg of 20% intravenous mannitol infusion over 10 minutes before induction of anesthesia (group M)
Study: 26446331
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg of 20% intravenous mannitol infusion (group M)
Study: 20230185
Drug: Steroid-free regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free regimen (Tacrolimus, Mycophenolate mofetil, Basiliximab induction, steroids for 3 days)
Study: 20230185
Drug: Steroid maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid maintenance regimen (Tacrolimus, Mycophenolate mofetil, Basiliximab induction, steroid maintenance)
Study: 18056435
Drug: High cysteinylglycine
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cysteinylglycine levels in the high alcohol intake group (>or=9 g/day)
Study: 10025442
Drug: 85.8 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 85.8 g amino acid mixture lacking tryptophan
Study: 31308304
Drug: Once-daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily insulin degludec/insulin aspart (IDegAsp), n = 26
Study: 31308304
Drug: Once-daily basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily basal insulin (insulin degludec and insulin glargine 300 units/mL), n = 26
Study: 25679398
Drug: Darbepoietin‐α treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darbepoietin‐α treatment
Study: 23594239
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 325 mg of aspirin (ASA)
Study: 21394642
Drug: Bradykinin (B(2)
Normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bradykinin (B(2) agonist)
Study: 21394642
Drug: Lys‐des‐Arg(9)‐bradykinin (B(1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lys‐des‐Arg(9)‐bradykinin (B(1) agonist)
Study: 19714604
Drug: Belimumab (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab (1, 4, or 10 mg/kg)
Study: 9784084
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg/day for 6 days
Study: 7929869
Drug: CL 275,838
Approvals — FDA: no, EMA: no, PMDA: no
Description: CL 275,838 (50 mg)
Study: 7929869
Drug: CL 275,838
Approvals — FDA: no, EMA: no, PMDA: no
Description: CL 275,838 (100 mg)
Study: 30591703
Drug: C₁‐L protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: C₁‐L protocol group (n=293)
Study: 30591703
Drug: OC‐L protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC‐L protocol group (n=91)
Study: 30591703
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol group (n=80)
Study: 27152422
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of IV dexamethasone before general anesthesia, BIS 35-45
Study: 27152422
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of IV dexamethasone before general anesthesia, BIS 46-55
Study: 24717957
Drug: Electrolyzed acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyzed acid water (EAW) nasal irrigation daily for 2 months
Study: 24717957
Drug: Neutral normal
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral normal saline (NS) nasal irrigation daily for 2 months
Study: 21996342
Drug: High-dose allergen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose allergen patches
Study: 15892409
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of i.v. lidocaine and nitrous oxide in oxygen inhalation
Study: 15892409
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide in oxygen inhalation
Study: 8941648
Drug: GBS type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS type III CPS‐tetanus toxoid conjugate (III‐TT) vaccine (highest dose)
Study: 6313595
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir 200 mg every 6 hours from day 8 to day 35 after transplantation
Study: 27333284
Drug: ivabradine 2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 2.5, 5, or 7.5 mg b.i.d. for 4 months
Study: 22606977
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support intervention (biweekly visits for 2 months, then weekly)
Study: 22606977
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (adherence counselling, monthly health check, drug refills)
Study: 20958200
Drug: Web-based self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based self-administered questionnaire (Web SAQ)
Study: 20958200
Drug: Paper-and-pencil self-administered
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-and-pencil self-administered questionnaire
Study: 17066232
Drug: Intra-arterial adjuvant
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial adjuvant chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5FU)
Study: 17066232
Drug: Intra-arterial adjuvant
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial adjuvant chemotherapy
Study: 15750369
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (flexion‐distraction chiropractic manipulation and trigger point therapy)
Study: 15750369
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (sham manipulation and effleurage)
Study: 4097650
Drug: Combined preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preparation of triiodothyronine and thyroxine (1:4 ratio)
Study: 30861580
Drug: Galcanezumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab (120 mg and 240 mg)
Study: 28113032
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg once per day for 5 years)
Study: 28113032
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg once per day for 5 years)
Study: 23279614
Drug: Tacrolimus twice
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus twice daily (control)
Study: 17250932
Drug: Zoster vaccine
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoster vaccine (approximately 50,000 PFU)
Study: 10665552
Drug: Aspirin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (80 mg orally twice daily)
Study: 10665552
Drug: Low-dose sibrafiban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sibrafiban (3.0 mg, 4.5 mg, or 6.0 mg)
Study: 10665552
Drug: High-dose sibrafiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sibrafiban (3.0 mg, 4.5 mg, or 6.0 mg)
Study: 10665552
Drug: High-dose sibrafiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sibrafiban
Study: 10665552
Drug: Low-dose sibrafiban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sibrafiban
Study: 9374092
Drug: Epirubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 75 mg/m2 as a 1-hour infusion followed by paclitaxel 200 mg/m2 as a 3-hour infusion every 3 weeks
Study: 9374092
Drug: Epirubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 75 mg/m2 plus paclitaxel 200 mg/m2
Study: 3884881
Drug: Protein excretion
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein excretion in transplant patients during pregnancy
Study: 3884881
Drug: Protein excretion
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein excretion in healthy women during pregnancy
Study: 27932335
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg apixaban, administered twice daily for 3 years as adjunct therapy to stable oral PAH therapy
Study: 27932335
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered twice daily for 3 years as adjunct therapy to stable oral PAH therapy
Study: 17868539
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose 4.5 g of azithromycin in 7 weeks
Study: 17868539
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose 6.0 g of azithromycin in 10 weeks
Study: 17868539
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose 7.5 g of azithromycin in 13 weeks
Study: 15167314
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta‐estradiol + 0.125 mg trimegestone (n = 179)
Study: 12851621
Drug: Lisinopril plus
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril plus isosorbide-5-mononitrate (IS5MN)
Study: 12851621
Drug: Lisinopril plus
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril plus IS5MN
Study: 1906258
Drug: Cefaclor (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (20 to 40 mg/kg/day in three divided doses for 10 days)
Study: 1906258
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (50,000 to 100,000 IU/kg/day in three divided doses for 10 days)
Study: 31350768
Drug: BDF +
Normalized name: LIME (CALCIUM OXIDE) 0.295 g in 100 mL ORAL SPRAY [BDFERM BIOSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDF + Oi (manual brushing/dental flossing + oral irrigator)
Study: 27505335
Drug: Intensive atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive atorvastatin (40mg)
Study: 27505335
Drug: Standard atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard atorvastatin (20mg)
Study: 16832679
Drug: gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil 600 mg orally twice daily for 3 days
Study: 14563899
Drug: co-amoxiclav 2000/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-amoxiclav 2000/125 mg twice daily
Study: 14563899
Drug: co-amoxiclav 875/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-amoxiclav 875/125 mg three times daily
Study: 2255839
Drug: Ivermectin 100
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 100 mcg/kg
Study: 1519031
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) 3 mg/kg
Study: 1480807
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) 3 mg/kg (3 successive semi-annual doses)
Study: 6529168
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of trimipramine in the evening
Study: 6529168
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of trimipramine three times daily
Study: 22987022
Drug: Atomoxetine 80
Normalized name: atomoxetine 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 80 mg daily followed by 100 mg daily for 5 days
Study: 22987022
Drug: Atomoxetine 80
Normalized name: atomoxetine 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 80 mg and 100 mg
Study: 16270222
Drug: Single-dose clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose clindamycin (600 mg 1 hour before surgery)
Study: 16270222
Drug: 24-hour clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour clindamycin prophylaxis (600 mg 1 hour before surgery, followed by 300 mg every 6 hours)
Study: 12358676
Drug: Naloxone (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (intravenous bolus followed by continuous infusion)
Study: 9697988
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous (Ci.v.) IL-2, n = 5
Study: 9697988
Drug: Subcutaneous infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infusions of polyethylene glycol-modified (PEG) IL-2, n = 7
Study: 9697988
Drug: Anti-viral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-viral therapy alone, n = 4
Study: 9697988
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (Ci.v. IL-2, PEG IL-2, anti-viral therapy)
Study: 266407
Drug: Active immunotherapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active immunotherapy (AI)
Study: 27810284
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (treatment-as-usual)
Study: 22952691
Drug: Internet-based guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based guided self-help problem-solving therapy (PST), consisting of 5 weekly lessons, supported by e-mail
Study: 15127339
Drug: Miltefosine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miltefosine (2.5 mg/kg per day orally for 28 days)
Study: 11868759
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg once daily for 5 days (n = 198)
Study: 11868759
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 500 mg three times daily for 10 days (n = 197)
Study: 7889960
Drug: Cefprozil 30
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil 30 mg/kg/day (b.i.d.)
Study: 7889960
Drug: Amoxicillin-clavulanate 40
Normalized name: amoxicillin-clavulanate 400 mg-57 mg oral tablet, chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate 40 mg/kg/day (t.i.d.)
Study: 7889960
Drug: Cefaclor 40
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor 40 mg/kg/day (t.i.d.)
Study: 7889960
Drug: Cefixime 8
Normalized name: cefixime 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 8 mg/kg/day (q.d.)
Study: 19939441
Drug: Diindolylmethane (DIM)
DrugBank: 3,3'-diindolylmethane (DB11875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diindolylmethane (DIM) at approximately 2 mg/kg/day for 12 weeks
Study: 6130952
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg cimetidine
Study: 7586949
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg cimetidine
Study: 7586949
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg cimetidine
Study: 208429
Drug: theophylline-ephedrine combination
Normalized name: Theophylline, Ephedrine Hydrochloride, and Phenobarbital Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: theophylline-ephedrine combination (theophylline 90 mg, ephedrine 16 mg and phenobarbital 25 mg in an immediate release layer and theophylline 90 mg and ephedrine 32 mg in a sustained release layer)
Study: 208429
Drug: terbutaline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbutaline (5 mg three times daily)
Study: 17935764
Drug: 300-index of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-index of reactivity (IR) dose
Study: 17935764
Drug: 500-index of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-index of reactivity (IR) dose
Study: 17935764
Drug: 100-index of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-index of reactivity (IR) dose
Study: 15016256
Drug: 1% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% metronidazole gel (MG, n=19)
Study: 15016256
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel (CG, n=20)
Study: 15016256
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (PG, n=24)
Study: 11716994
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal 17beta‐estradiol 50 mcg/die plus acetate nomegestrolo 5 mg/die sequentially added for 12 days per month (Group A)
Study: 11716994
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal 17beta‐estradiol 50 mcg/die plus acetate nomegestrolo 2.5 mg/die added every day (Group B)
Study: 11716994
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal 17beta‐estradiol 50 mcg/die (Group C)
Study: 11716994
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg/die (Group D)
Study: 11716994
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (Control Group E)
Study: 8021039
Drug: Dental gel
Normalized name: DENTAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental gel
Study: 2530547
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg/day (single daily dose)
Study: 2530547
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg/day (two divided doses)
Study: 1190691
Drug: Vasectomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasectomy and irrigation of distal vasa with acid Kystosol solution
Study: 22119995
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) chemotherapy
Study: 25959002
Drug: Overall chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall chemotherapy (both IV and oral)
Study: 21726499
Drug: Clindox® 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindox® 150 mg capsule (test)
Study: 21726499
Drug: Dalacin C®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalacin C® 150 mg capsule (reference)
Study: 16184460
Drug: Exemestane (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25 mg/day)
Study: 16707074
Drug: New atypical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New atypical drugs
Study: 16707074
Drug: New atypical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New atypical drugs (band 2)
Study: 15531010
Drug: 4 NaP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 NaP tablets (1.5 g NaP/tablet) each morning for 28 days (group A)